OverviewSuggest Edit

Kiromic BioPharma (formerly known as Kiromic) is a target discovery and gene editing company focusing on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. It develops an allogeneic chimeric antigen receptor (CAR) cell product candidate against cancer, a checkpoint inhibitor for solid tumors, as well as oral healthcare products. The company also offers DIAMOND AI (Kiromic Diamond Artificial Intelligence), a multi-purpose computational platform that can identify cancer immunological targets for T-Cells and B-Cells.

TypePublic
Founded2012
HQHouston, TX, US
Websitekiromic.com

Locations

Kiromic Biopharma is headquartered in
Houston, United States

Location Map

Latest Updates

Employees (est.) (Oct 2020)13
Job Openings2
Share Price (Jul 2021)$3.2(-3%)
Cybersecurity ratingBMore

Key People/Management at Kiromic Biopharma

Maurizio Chiriva-Internati

Maurizio Chiriva-Internati

Chairman & CEO
Gianluca Rotino

Gianluca Rotino

CSIO
Scott Dahlbeck

Scott Dahlbeck

CMO
Jerry Schneider

Jerry Schneider

Independent Director
Pietro Bersani

Pietro Bersani

Director
Michael Nagel

Michael Nagel

Independent Director
Show more

Kiromic Biopharma Office Locations

Kiromic Biopharma has an office in Houston
Houston, TX, US (HQ)
7707 Fannin St Suite 140
Show all (1)

Kiromic Biopharma Financials and Metrics

Kiromic Biopharma Revenue

USD

Net income (FY, 2020)

(19.2m)

EBIT (FY, 2020)

(19.2m)

Market capitalization (29-Jul-2021)

23.2m

Closing stock price (29-Jul-2021)

3.2

Cash (31-Dec-2020)

10.2m

EV

13.5m
Kiromic Biopharma's current market capitalization is $23.2 m.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

1.8m2.5m14.1m

R&D expense

1.4m1.2m5.1m

Operating expense total

3.2m3.7m19.2m

EBIT

(3.2m)(3.7m)(19.2m)
Quarterly
USDQ2, 2019Q3, 2019Q2, 2020Q3, 2020

General and administrative expense

143.1k1.2m10.1m607.4k

R&D expense

125.9k1.2m1.3m272.1k

Operating expense total

269.0k2.4m11.4m879.5k

EBIT

(269.0k)(2.4m)(11.4m)(879.5k)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

384.3k1.9m10.2m

Prepaid Expenses

588.8k

Inventories

16.3k22.2k

Current Assets

560.2k2.0m10.7m
Quarterly
USDQ3, 2020Q3, 2020

Cash

1.7m469.3k

Inventories

22.2k22.2k

Current Assets

2.5m1.5m

PP&E

1.3m1.6m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(3.8m)(3.7m)(19.2m)

Depreciation and Amortization

80.9k87.5k200.0k

Inventories

(5.9k)

Accounts Payable

(4.4k)293.4k(7.7k)
Quarterly
USDQ2, 2019Q3, 2019Q2, 2020Q3, 2020

Net Income

(671.3k)(1.6m)(13.2m)(15.6m)

Depreciation and Amortization

43.0k63.7k68.5k118.9k

Inventories

(5.9k)(5.9k)

Accounts Payable

(98.2k)226.1k291.0k398.3k
USDFY, 2018

Financial Leverage

3.3 x
Show all financial metrics

Kiromic Biopharma Operating Metrics

Q2, 2020

Research Stage Products

2

Preclinical Phase Products

2
Show all operating metrics

Kiromic Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Kiromic Biopharma Online and Social Media Presence

Embed Graph

Kiromic Biopharma Frequently Asked Questions

  • When was Kiromic Biopharma founded?

    Kiromic Biopharma was founded in 2012.

  • Who are Kiromic Biopharma key executives?

    Kiromic Biopharma's key executives are Maurizio Chiriva-Internati, Gianluca Rotino and Scott Dahlbeck.

  • How many employees does Kiromic Biopharma have?

    Kiromic Biopharma has 13 employees.

  • Who are Kiromic Biopharma competitors?

    Competitors of Kiromic Biopharma include Xilio Therapeutics, RAPT Therapeutics and Alligator Bioscience.

  • Where is Kiromic Biopharma headquarters?

    Kiromic Biopharma headquarters is located at 7707 Fannin St Suite 140, Houston.

  • Where are Kiromic Biopharma offices?

    Kiromic Biopharma has an office in Houston.

  • How many offices does Kiromic Biopharma have?

    Kiromic Biopharma has 1 office.